These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. Mukherjee J; Kozel TR; Casadevall A J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877 [TBL] [Abstract][Full Text] [Related]
6. Cryptococcus neoformans infection can elicit protective antibodies in mice. Mukherjee J; Scharff MD; Casadevall A Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967 [TBL] [Abstract][Full Text] [Related]
7. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies. Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763 [TBL] [Abstract][Full Text] [Related]
8. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi? Pirofski LA; Casadevall A Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968 [TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. Taborda CP; Casadevall A J Immunol; 2001 Feb; 166(3):2100-7. PubMed ID: 11160261 [TBL] [Abstract][Full Text] [Related]
10. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Zebedee SL; Koduri RK; Mukherjee J; Mukherjee S; Lee S; Sauer DF; Scharff MD; Casadevall A Antimicrob Agents Chemother; 1994 Jul; 38(7):1507-14. PubMed ID: 7979280 [TBL] [Abstract][Full Text] [Related]
11. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Yuan RR; Spira G; Oh J; Paizi M; Casadevall A; Scharff MD Infect Immun; 1998 Mar; 66(3):1057-62. PubMed ID: 9488395 [TBL] [Abstract][Full Text] [Related]
12. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. Mukherjee J; Casadevall A; Scharff MD J Exp Med; 1993 Apr; 177(4):1105-16. PubMed ID: 8459205 [TBL] [Abstract][Full Text] [Related]
14. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. Beenhouwer DO; May RJ; Valadon P; Scharff MD J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134 [TBL] [Abstract][Full Text] [Related]
15. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223 [TBL] [Abstract][Full Text] [Related]
17. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans. Todaro-Luck F; White EH; Reiss E; Cherniak R Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437 [TBL] [Abstract][Full Text] [Related]
18. Antibody interactions with the capsule of Cryptococcus neoformans. Feldmesser M; Rivera J; Kress Y; Kozel TR; Casadevall A Infect Immun; 2000 Jun; 68(6):3642-50. PubMed ID: 10816523 [TBL] [Abstract][Full Text] [Related]
19. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Zaragoza O; Casadevall A Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]